MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers

Ghadjar, Pirus; Blank-Liss, Wieslawa; Simcock, Mathew; Hegyi, Ivan; Beer, Karl T; Moch, Holger; Aebersold, Daniel M; Zimmer, Yitzhak (2009). MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clinical & experimental metastasis, 26(7), pp. 809-15. Dordrecht: Springer Netherlands 10.1007/s10585-009-9280-9

[img]
Preview
Text
10585_2009_Article_9280.pdf - Published Version
Available under License Publisher holds Copyright.

Download (213kB) | Preview

We investigated if the MET-activating point mutation Y1253D influences clinical outcomes in patients with advanced squamous cell carcinoma of the head and neck (HNSCC). The study population consisted of 152 HNSCC patients treated by hyperfractionated radiotherapy alone or concomitant with chemotherapy between September 1994 and July 2000. Tumors were screened for the presence of the MET-activating point mutation Y1253D. Seventy-eight patients (51%) received radiotherapy alone, 74 patients (49%) underwent radiotherapy concomitant with chemotherapy. Median patient age was 54 years and median follow-up was 5.5 years. Distant metastasis-free survival, local relapse-free survival and overall survival were compared with MET Y1253D status. During follow-up, 29 (19%) patients developed distant metastasis. MET Y1253D was detected in tumors of 21 out of 152 patients (14%). Distant metastasis-free survival (P = 0.008) was associated with MET Y1253D. In a multivariate Cox regression model, adjusted for T-category, only presence of MET Y1253D was associated with decreased distant metastasis-free survival: hazard ratio = 2.5 (95% confidence interval: 1.1, 5.8). The observed association between MET Y1253D-activating point mutation and decreased distant metastasis-free survival in advanced HNSCC suggests that MET may be a potential target for specific treatment interventions.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Ghadjar, Pirus; Hegyi, Ivan; Aebersold, Daniel and Zimmer, Yitzhak

ISSN:

0262-0898

Publisher:

Springer Netherlands

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:12

Last Modified:

26 Jun 2018 15:01

Publisher DOI:

10.1007/s10585-009-9280-9

PubMed ID:

19639388

Web of Science ID:

000271722300022

BORIS DOI:

10.7892/boris.31641

URI:

https://boris.unibe.ch/id/eprint/31641 (FactScience: 196286)

Actions (login required)

Edit item Edit item
Provide Feedback